Novartis Pluvicto demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer
Ad hoc announcement pursuant to Art. 53 LR At interim analysis, PSMAddition…
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd (“Avistone”), an innovative biotechnology company focused…
HUTCHMED Completes Patient Enrollment of a PhaseII Registration Study of SavolitinibinGastricCancer inChina
April 21, 2025 20:00 ET | Source: HUTCHMED (China) Limited HONG KONG…
Bybit’s CEO Meets with Vietnam’s Minister of Finance to Support Regulatory Sandbox and Strengthen Crypto Compliance
DUBAI, UAE, April 19, 2025 /PRNewswire/ -- Ben Zhou, Co-founder and CEO…
With 36% growth, APRIL reaffirms its ambition to become Europe’s leading world-class insurance broker in the mass market
LYON, France, April 9, 2025 /PRNewswire/ -- One year after launching its…
GAC Accelerates European Expansion as AION UT and AION V Shine at Milan Design Week
MILAN, April 8, 2025 /PRNewswire/ -- On April 8th, during Milan Design…
Arjun Kapoor’s Fierce Villain Avatar in ‘Singham Again’, Trailer Leaves Fans Loving the New Look and Intrigued to See More
Arjun Kapoor as Danger Lanka, the menacing antagonist in the upcoming film…
Segway Hosts 2025 APAC & MET Distributors’ Conference in Istanbul
ENGAGE • EXPLORE • EVOLVE – Unveiling the Next Chapter of Innovation…
Incyte Announces Results of Phase 3 Clinical Trials Evaluating Ruxolitinib Cream 1.5% (Opzelura) in Patients with Prurigo Nodularis (PN) at 2025 American Academy of Dermatology Annual Meeting
- Full data from the Phase 3 TRuE-PN1 study, presented today in…
Port Houston Celebrates Record-Breaking Performance, Major Milestones
Port Commission’s Meeting Spotlights Leadership, Community and Employee RecognitionHOUSTON--(BUSINESS WIRE)--On Wednesday, February…